IGF2BP3 and gastric cancer: Importantly, in vivo experiments demonstrated that re-expressed IGF2BP3 partly abolished the anti-carcinogenic function of miR-34a, further emphasizing that IGF2BP3 was the bona fide functional target of miR-34a in GC (Fig. 7e).